Markowska A, Lubin J, Madry R, Markowska J
Department of Perinatology and Gynecology, Karol Marcinkowski University of Medical Science, Poznań.
Eur J Gynaecol Oncol. 2013;34(4):303-6.
Angiogenesis is a dynamic process which leads to a development of cancer and metastases. The most recognized and dominant prognostic factor is vascular endothelial growth factor (VEGF) and its receptors. VEGF was identyfied in 1989. There are three receptors for VEGF: VEGFR1 (VEGF receptor 1) and VEGFR2 that play the role in angiogenesis and development of ascites, and VEGFR3 is critical for lymphangiogenesis. There is bevacizumab--a new drug, monoclonal antibody that can block connection VEGF to its receptors. The first notification of activity of bevacizumab in ovarian cancer was in 2005. The aim of the article is to show some clinical trials in ovarian cancer and their results. The bevacizumab was registered in November 2011 in first line with standard chemotherapy in ovarian cancer. There is a new weapon against this disease.
血管生成是一个动态过程，它会导致癌症的发展和转移。最广为人知且占主导地位的预后因素是血管内皮生长因子（VEGF）及其受体。VEGF于1989年被发现。VEGF有三种受体：VEGFR1（VEGF受体1）和VEGFR2，它们在血管生成和腹水形成中起作用，而VEGFR3对淋巴管生成至关重要。有一种新药贝伐单抗，它是一种单克隆抗体，可以阻断VEGF与其受体的连接。贝伐单抗在卵巢癌中的活性首次报道是在2005年。本文的目的是展示一些卵巢癌的临床试验及其结果。贝伐单抗于2011年11月在卵巢癌一线治疗中与标准化疗联合获批。这是对抗这种疾病的一种新武器。
